US 11,834,498 B2
Biparatopic FR-alpha antibodies and immunoconjugates
Olga Ab, Millis, MA (US); Neeraj Kohli, Arlington, MA (US); Thomas Chittenden, Sudbury, MA (US); and Julianto Setiady, Lexington, MA (US)
Assigned to ImmunoGen, Inc., Waltham, MA (US)
Filed by ImmunoGen, Inc., Waltham, MA (US)
Filed on Jun. 10, 2022, as Appl. No. 17/838,016.
Application 17/838,016 is a continuation of application No. 16/860,822, filed on Apr. 28, 2020, granted, now 11,396,543.
Claims priority of provisional application 62/879,864, filed on Jul. 29, 2019.
Claims priority of provisional application 62/840,297, filed on Apr. 29, 2019.
Prior Publication US 2023/0085779 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 31/5365 (2006.01); A61P 35/00 (2006.01); A61K 47/68 (2017.01)
CPC C07K 16/28 (2013.01) [A61K 31/5365 (2013.01); A61K 47/6803 (2017.08); A61P 35/00 (2018.01); C07K 2317/31 (2013.01); C07K 2317/569 (2013.01)] 30 Claims
 
1. A method of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an immunoconjugate represented by the following formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
CBA is a biparatopic antibody or an antigen-binding fragment comprising the amino acid sequences of SEQ ID NOs: 41-43;
D1 is represented by the following formula:

OG Complex Work Unit Chemistry
 and
q is an integer from 1 to 10, wherein said cancer is a human folate receptor 1 (FRα) expressing cancer.